Report cover image

Global Diabetes Medicines Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 118 Pages
SKU # APRC20353744

Description

Summary

According to APO Research, The global Diabetes Medicines market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Diabetes Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Diabetes Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Diabetes Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Diabetes Medicines include Biocon, Boehringer Ingelheim, Geropharm, Wockhardt, AstraZeneca, bayer, Ganli Pharmaceutical, Jiangsu Wanbang and Conker Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Diabetes Medicines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetes Medicines.

The Diabetes Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Diabetes Medicines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Diabetes Medicines Segment by Company

Biocon
Boehringer Ingelheim
Geropharm
Wockhardt
AstraZeneca
bayer
Ganli Pharmaceutical
Jiangsu Wanbang
Conker Pharmaceuticals
Eli Lilly
United Pharmaceuticals
Merck Serono
Merck
Novo Nordisk
Novartis
Johnson & Johnson
Sanofi
Tonghua Dongbao
Takeda

Diabetes Medicines Segment by Type

Oral
Injection

Diabetes Medicines Segment by Application

Hospital
Retail Pharmacy

Diabetes Medicines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetes Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetes Medicines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Diabetes Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

118 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Diabetes Medicines Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Diabetes Medicines Sales Estimates and Forecasts (2020-2031)
1.3 Diabetes Medicines Market by Type
1.3.1 Oral
1.3.2 Injection
1.4 Global Diabetes Medicines Market Size by Type
1.4.1 Global Diabetes Medicines Market Size Overview by Type (2020-2031)
1.4.2 Global Diabetes Medicines Historic Market Size Review by Type (2020-2025)
1.4.3 Global Diabetes Medicines Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Diabetes Medicines Sales Breakdown by Type (2020-2025)
1.5.2 Europe Diabetes Medicines Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Diabetes Medicines Sales Breakdown by Type (2020-2025)
1.5.4 South America Diabetes Medicines Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Diabetes Medicines Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Diabetes Medicines Industry Trends
2.2 Diabetes Medicines Industry Drivers
2.3 Diabetes Medicines Industry Opportunities and Challenges
2.4 Diabetes Medicines Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Diabetes Medicines Revenue (2020-2025)
3.2 Global Top Players by Diabetes Medicines Sales (2020-2025)
3.3 Global Top Players by Diabetes Medicines Price (2020-2025)
3.4 Global Diabetes Medicines Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Diabetes Medicines Major Company Production Sites & Headquarters
3.6 Global Diabetes Medicines Company, Product Type & Application
3.7 Global Diabetes Medicines Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Diabetes Medicines Market CR5 and HHI
3.8.2 Global Top 5 and 10 Diabetes Medicines Players Market Share by Revenue in 2024
3.8.3 2023 Diabetes Medicines Tier 1, Tier 2, and Tier 3
4 Diabetes Medicines Regional Status and Outlook
4.1 Global Diabetes Medicines Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Diabetes Medicines Historic Market Size by Region
4.2.1 Global Diabetes Medicines Sales in Volume by Region (2020-2025)
4.2.2 Global Diabetes Medicines Sales in Value by Region (2020-2025)
4.2.3 Global Diabetes Medicines Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Diabetes Medicines Forecasted Market Size by Region
4.3.1 Global Diabetes Medicines Sales in Volume by Region (2026-2031)
4.3.2 Global Diabetes Medicines Sales in Value by Region (2026-2031)
4.3.3 Global Diabetes Medicines Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Diabetes Medicines by Application
5.1 Diabetes Medicines Market by Application
5.1.1 Hospital
5.1.2 Retail Pharmacy
5.2 Global Diabetes Medicines Market Size by Application
5.2.1 Global Diabetes Medicines Market Size Overview by Application (2020-2031)
5.2.2 Global Diabetes Medicines Historic Market Size Review by Application (2020-2025)
5.2.3 Global Diabetes Medicines Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Diabetes Medicines Sales Breakdown by Application (2020-2025)
5.3.2 Europe Diabetes Medicines Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Diabetes Medicines Sales Breakdown by Application (2020-2025)
5.3.4 South America Diabetes Medicines Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Diabetes Medicines Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Biocon
6.1.1 Biocon Comapny Information
6.1.2 Biocon Business Overview
6.1.3 Biocon Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Biocon Diabetes Medicines Product Portfolio
6.1.5 Biocon Recent Developments
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Comapny Information
6.2.2 Boehringer Ingelheim Business Overview
6.2.3 Boehringer Ingelheim Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Boehringer Ingelheim Diabetes Medicines Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments
6.3 Geropharm
6.3.1 Geropharm Comapny Information
6.3.2 Geropharm Business Overview
6.3.3 Geropharm Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Geropharm Diabetes Medicines Product Portfolio
6.3.5 Geropharm Recent Developments
6.4 Wockhardt
6.4.1 Wockhardt Comapny Information
6.4.2 Wockhardt Business Overview
6.4.3 Wockhardt Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Wockhardt Diabetes Medicines Product Portfolio
6.4.5 Wockhardt Recent Developments
6.5 AstraZeneca
6.5.1 AstraZeneca Comapny Information
6.5.2 AstraZeneca Business Overview
6.5.3 AstraZeneca Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Diabetes Medicines Product Portfolio
6.5.5 AstraZeneca Recent Developments
6.6 bayer
6.6.1 bayer Comapny Information
6.6.2 bayer Business Overview
6.6.3 bayer Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.6.4 bayer Diabetes Medicines Product Portfolio
6.6.5 bayer Recent Developments
6.7 Ganli Pharmaceutical
6.7.1 Ganli Pharmaceutical Comapny Information
6.7.2 Ganli Pharmaceutical Business Overview
6.7.3 Ganli Pharmaceutical Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Ganli Pharmaceutical Diabetes Medicines Product Portfolio
6.7.5 Ganli Pharmaceutical Recent Developments
6.8 Jiangsu Wanbang
6.8.1 Jiangsu Wanbang Comapny Information
6.8.2 Jiangsu Wanbang Business Overview
6.8.3 Jiangsu Wanbang Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Jiangsu Wanbang Diabetes Medicines Product Portfolio
6.8.5 Jiangsu Wanbang Recent Developments
6.9 Conker Pharmaceuticals
6.9.1 Conker Pharmaceuticals Comapny Information
6.9.2 Conker Pharmaceuticals Business Overview
6.9.3 Conker Pharmaceuticals Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Conker Pharmaceuticals Diabetes Medicines Product Portfolio
6.9.5 Conker Pharmaceuticals Recent Developments
6.10 Eli Lilly
6.10.1 Eli Lilly Comapny Information
6.10.2 Eli Lilly Business Overview
6.10.3 Eli Lilly Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly Diabetes Medicines Product Portfolio
6.10.5 Eli Lilly Recent Developments
6.11 United Pharmaceuticals
6.11.1 United Pharmaceuticals Comapny Information
6.11.2 United Pharmaceuticals Business Overview
6.11.3 United Pharmaceuticals Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.11.4 United Pharmaceuticals Diabetes Medicines Product Portfolio
6.11.5 United Pharmaceuticals Recent Developments
6.12 Merck Serono
6.12.1 Merck Serono Comapny Information
6.12.2 Merck Serono Business Overview
6.12.3 Merck Serono Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Merck Serono Diabetes Medicines Product Portfolio
6.12.5 Merck Serono Recent Developments
6.13 Merck
6.13.1 Merck Comapny Information
6.13.2 Merck Business Overview
6.13.3 Merck Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Merck Diabetes Medicines Product Portfolio
6.13.5 Merck Recent Developments
6.14 Novo Nordisk
6.14.1 Novo Nordisk Comapny Information
6.14.2 Novo Nordisk Business Overview
6.14.3 Novo Nordisk Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Novo Nordisk Diabetes Medicines Product Portfolio
6.14.5 Novo Nordisk Recent Developments
6.15 Novartis
6.15.1 Novartis Comapny Information
6.15.2 Novartis Business Overview
6.15.3 Novartis Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Novartis Diabetes Medicines Product Portfolio
6.15.5 Novartis Recent Developments
6.16 Johnson & Johnson
6.16.1 Johnson & Johnson Comapny Information
6.16.2 Johnson & Johnson Business Overview
6.16.3 Johnson & Johnson Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Johnson & Johnson Diabetes Medicines Product Portfolio
6.16.5 Johnson & Johnson Recent Developments
6.17 Sanofi
6.17.1 Sanofi Comapny Information
6.17.2 Sanofi Business Overview
6.17.3 Sanofi Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Sanofi Diabetes Medicines Product Portfolio
6.17.5 Sanofi Recent Developments
6.18 Tonghua Dongbao
6.18.1 Tonghua Dongbao Comapny Information
6.18.2 Tonghua Dongbao Business Overview
6.18.3 Tonghua Dongbao Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Tonghua Dongbao Diabetes Medicines Product Portfolio
6.18.5 Tonghua Dongbao Recent Developments
6.19 Takeda
6.19.1 Takeda Comapny Information
6.19.2 Takeda Business Overview
6.19.3 Takeda Diabetes Medicines Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Takeda Diabetes Medicines Product Portfolio
6.19.5 Takeda Recent Developments
7 North America by Country
7.1 North America Diabetes Medicines Sales by Country
7.1.1 North America Diabetes Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Diabetes Medicines Sales by Country (2020-2025)
7.1.3 North America Diabetes Medicines Sales Forecast by Country (2026-2031)
7.2 North America Diabetes Medicines Market Size by Country
7.2.1 North America Diabetes Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Diabetes Medicines Market Size by Country (2020-2025)
7.2.3 North America Diabetes Medicines Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Diabetes Medicines Sales by Country
8.1.1 Europe Diabetes Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Diabetes Medicines Sales by Country (2020-2025)
8.1.3 Europe Diabetes Medicines Sales Forecast by Country (2026-2031)
8.2 Europe Diabetes Medicines Market Size by Country
8.2.1 Europe Diabetes Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Diabetes Medicines Market Size by Country (2020-2025)
8.2.3 Europe Diabetes Medicines Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Diabetes Medicines Sales by Country
9.1.1 Asia-Pacific Diabetes Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Diabetes Medicines Sales by Country (2020-2025)
9.1.3 Asia-Pacific Diabetes Medicines Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Diabetes Medicines Market Size by Country
9.2.1 Asia-Pacific Diabetes Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Diabetes Medicines Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Diabetes Medicines Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Diabetes Medicines Sales by Country
10.1.1 South America Diabetes Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Diabetes Medicines Sales by Country (2020-2025)
10.1.3 South America Diabetes Medicines Sales Forecast by Country (2026-2031)
10.2 South America Diabetes Medicines Market Size by Country
10.2.1 South America Diabetes Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Diabetes Medicines Market Size by Country (2020-2025)
10.2.3 South America Diabetes Medicines Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Diabetes Medicines Sales by Country
11.1.1 Middle East and Africa Diabetes Medicines Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Diabetes Medicines Sales by Country (2020-2025)
11.1.3 Middle East and Africa Diabetes Medicines Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Diabetes Medicines Market Size by Country
11.2.1 Middle East and Africa Diabetes Medicines Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Diabetes Medicines Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Diabetes Medicines Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Diabetes Medicines Value Chain Analysis
12.1.1 Diabetes Medicines Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Diabetes Medicines Production Mode & Process
12.2 Diabetes Medicines Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Diabetes Medicines Distributors
12.2.3 Diabetes Medicines Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.